智通财经APP讯,恒瑞医药(01276)发布公告,截至本公告披露日,公司2022年员工持股计划第三个锁定期实际解锁股份共计283.03万股(占目前公司总股本的0.04%)。截至2025年11月14日,165.68万股非交易过户至员工持股计划份额持有人,117.35万股通过集中竞价交易方式出售。公司2022年员工持股计划管理委员会后续将根据本次员工持股计划的相关约定进行相应财产分配工作。
智通财经APP讯,恒瑞医药(01276)发布公告,截至本公告披露日,公司2022年员工持股计划第三个锁定期实际解锁股份共计283.03万股(占目前公司总股本的0.04%)。截至2025年11月14日,165.68万股非交易过户至员工持股计划份额持有人,117.35万股通过集中竞价交易方式出售。公司2022年员工持股计划管理委员会后续将根据本次员工持股计划的相关约定进行相应财产分配工作。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.